Weekly
Explores AI's role in robotics, with spotlights on humanoid breakthroughs (e.g., single-model training for movements) and broader implications like workforce integration. Includes reader Q&A on robot 'breakthroughs.'
AI
Robotics & Automation
Tech Trends
Daily/Weekly
Daily/weekly robotics news digest, heavy on humanoid updates from global players, including Chinese firms like Unitree, with analysis on hardware, software, and events like CES or UFC demos.
Robotics & Automation
AI
Business & Startups
Weekly
AI and robotics-focused, covering humanoid 'revolutions' from bartenders to surgical aides, with exclusive interviews and trends like Tesla's Optimus scaling.
AI
Robotics & Automation
Business & Startups
Monthly
A newsletter co-hosted by the Wyss Institute at Harvard University, focusing on the intersection of AI, biology, and healthcare to transform medicine, with emphasis on AI-driven drug discovery and accelerating life-saving therapies.
AI
Biotechnology & Medicine
Longevity Escape Velocity
Daily
Daily insights into health care innovations, including AI's role in drug discovery, repurposing existing drugs for rare diseases, and accelerating treatments for conditions like idiopathic pulmonary fibrosis and ALS.
AI
Longevity Escape Velocity
Biotechnology & Medicine
Weekly
Top stories in biotechnology, drug discovery, and pharma, highlighting AI-enabled milestones like clinical trials for AI-discovered drugs targeting idiopathic pulmonary fibrosis and regulatory challenges in AI therapeutics.
AI
Biotechnology & Medicine
Clinical Trials
Daily
Breaking news and breakthroughs on AI applications in healthcare, covering precision medicine, AI-discovered drugs for cancer and neurological disorders, and accelerated timelines in psychiatric drug design.
AI
Longevity Escape Velocity
Biotechnology & Medicine
Annual
UCLA researchers developed PP405, a topical molecule that inhibits the SCUBE3 protein to 'wake up' dormant hair follicle stem cells, promoting regrowth. Phase 1 trials showed safety and follicle activation in humans within a week; Phase 3 starts in 2026. Effective in mice for full reversal, with potential to regrow hair on scarred scalps.
Longevity Escape Velocity
Clinical Trials